Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C9H13NO |
| Molecular Weight | 151.2056 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(N)CC1=CC=C(O)C=C1
InChI
InChIKey=GIKNHHRFLCDOEU-UHFFFAOYSA-N
InChI=1S/C9H13NO/c1-7(10)6-8-2-4-9(11)5-3-8/h2-5,7,11H,6,10H2,1H3
Hydroxyamphetamine is a derivative of amphetamines. Hydroxyamphetamine is intended mainly as local eye drops for diagnostic purposes. It is indirect sympathomimetic agent which cause dilation of the eye pupil before diagnostic test. Among the minor side effects from its use are: change in color vision, difficulty seeing at night, dry mouth, headache, increased sensitivity of eyes to sunlight, muscle stiffness or tightness and temporary stinging in the eyes. The main use of hydroxyamphetamines as eye drops is the diagnosis of Horner's syndrome which is characterized by nerve lesions. Hydroxyamphetamine hydrobromide is a component of FDA approved brand drug - Paremyd sterile ophthalmic solution (Hydroxyamphetamine hydrobromide, USP 1.0%, Tropicamide, USP 0.25%). Hydroxyamphetamine is an indirect-acting sympathomimetic, while tropicamide acts as a parasympatholytic.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Diagnostic | Paremyd Approved UsePAREMYD Solution is indicated for mydriasis in routine diagnostic procedures and in conditions
where short-term pupil dilation is desired. PAREMYD provides clinically significant mydriasis with
partial cycloplegia. Launch Date1992 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/13143480/ |
10 mg/kg bw single, intravenous dose: 10 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROXYAMPHETAMINE plasma | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/13143480/ |
10 mg/kg bw single, intravenous dose: 10 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROXYAMPHETAMINE plasma | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/13143480/ |
10 mg/kg bw single, intravenous dose: 10 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROXYAMPHETAMINE plasma | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The correlation of phenylephrine 1% with hydroxyamphetamine 1% in Horner's syndrome. | 2004 Apr |
|
| Prolactinoma presenting as painful postganglionic Horner syndrome. | 2004 Apr 27 |
|
| Monoamine oxidase and head-twitch response in mice. Mechanisms of alpha-methylated substrate derivatives. | 2004 Jan |
|
| A study of the metabolism of methamphetamine and 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in isolated rat hepatocytes. | 2005 Mar 10 |
|
| Cation-selective exhaustive injection and sweeping MEKC for direct analysis of methamphetamine and its metabolites in urine. | 2006 Dec |
|
| Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine. | 2007 Apr |
|
| Novel biomarkers of prenatal methamphetamine exposure in human meconium. | 2009 Feb |
Patents
Sample Use Guides
Mydriasis: Ophthalmic: Instill 1 to 2 drops into conjunctival sac(s)
Route of Administration:
Topical
SH-SY5Y neurons were incubated with Hydroxyamphetamine (concentration range 0-10mM) for 24 or 48h, and the viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and lactate dehydrogenase (LDH) leakage assays.. For Hydroxyamphetamine the TC50 was not reached in the tested concentration range. Hydroxyamphetamine at 8.00mM originated few late apoptotic cells
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29747
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
||
|
NDF-RT |
N0000000122
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
||
|
NDF-RT |
N0000175883
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
4-Hydroxyamphetamine
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
PRIMARY | |||
|
DB09352
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
PRIMARY | |||
|
136
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
PRIMARY | |||
|
DTXSID3023134
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
PRIMARY | |||
|
100000084199
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
PRIMARY | |||
|
103-86-6
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
PRIMARY | |||
|
203-152-8
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
PRIMARY | |||
|
C61787
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
PRIMARY | |||
|
1394
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
PRIMARY | |||
|
3651
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
PRIMARY | |||
|
SUB08075MIG
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
PRIMARY | |||
|
D010136
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
PRIMARY | |||
|
CHEMBL1546
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
PRIMARY | |||
|
m6117
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
PRIMARY | Merck Index | ||
|
170995
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
PRIMARY | |||
|
7839
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
PRIMARY | RxNorm | ||
|
FQR280JW2N
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
PRIMARY | |||
|
FQR280JW2N
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
PRIMARY | |||
|
1518-86-1
Created by
admin on Fri Dec 15 18:56:03 GMT 2023 , Edited by admin on Fri Dec 15 18:56:03 GMT 2023
|
SUPERSEDED |
ACTIVE MOIETY
PARENT (METABOLITE ACTIVE)
PARENT (METABOLITE)
PARENT (METABOLITE)
SALT/SOLVATE (PARENT)
